Tarsus Pharmaceuticals, Inc. (TARS) shares ended the last trading session 10.9% higher at $65.17. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.3% gain over the past four weeks.The sudden rise in the stock price can be attributed to the growing investor optimism regarding the continued strong uptake of Tarsus Pharmaceuticals’ only marketed product, Xdemvy (lotilaner ophthalmic solution) 0.25%, approved for trea ...